Onradivir (INN) is an antiviral drug. In China it is approved for the treatment of influenza A infections in adults, excluding those at high risk for influenza-related complications. It acts as an inhibitor of influenza virus polymerase basic protein 2 (PB2), a crucial subunit of the virus' RNA polymerase complex. It is being developed by Guangdong Raynovent Biotech. It is derived from pimodivir and has high chemical similarity to it.
References


